FINNENCE ▪ THE WIRE FILE
THE WIRE · № 81933
News■ Unclear/unknown
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Labcorp asset purchase expands lab testing footprint; OPKO divests BioReference assets.
Diagnostics consolidation continues; terms undisclosed
CATALYST TO WATCH
Deal close and integration details
MAIN RISK
Financial terms not disclosed in text
FULL DISPATCH
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals2026-10-15 12:00 UTC
New Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity — Pfizer2026-10-15 12:00 UTC
New Phase 3 trial: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity — Pfizer2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia — Shanghai RAAS Blood Products Co., Ltd.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia — Shanghai RAAS Blood Products Co., Ltd.2026-10-15 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.